Amphastar Pharmaceuticals (AMPH) Receivables - Net (2013 - 2026)

Amphastar Pharmaceuticals' Receivables - Net history runs 14 years deep, the most recent figure standing at $147.8 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 2.22% year-over-year to $147.8 million; the TTM figure through Mar 2026 stood at $147.8 million (up 2.22% YoY), while the FY2025 annual figure was $143.6 million, up 5.33% from the prior year.
• Receivables - Net was $147.8 million for Q1 2026 at Amphastar Pharmaceuticals, up from $143.6 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $147.8 million in Q1 2026 to a low of $73.2 million in Q1 2022.
• Historically, Receivables - Net has averaged $118.8 million across 5 years, with a median of $131.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net fell 6.12% in 2022, then soared 54.33% in 2023.
• A 5-year view of Receivables - Net shows it stood at $88.8 million in 2022, then rose by 29.43% to $114.9 million in 2023, then rose by 18.57% to $136.3 million in 2024, then increased by 5.33% to $143.6 million in 2025, then climbed by 2.99% to $147.8 million in 2026.
• The last three Receivables - Net figures came in at $147.8 million (Q1 2026), $143.6 million (Q4 2025), and $146.8 million (Q3 2025), per Business Quant data.